Investors

investor-photo2

Enanta Pharmaceuticals is a clinical stage biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. Enanta’s research and development is currently focused on the following disease targets: respiratory syncytial virus (RSV), SARS-CoV-2 (C0VID-19), hepatitis B Virus (HBV) and human metapneumovirus (hMPV).

Learn More »

Volume:

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent Press Releases

May 18, 2022
Enanta Pharmaceuticals Reports Topline Data from the RSVP Study of EDP-938 in Otherwise Healthy Adults with Community-Acquired Respiratory Syncytial Virus (RSV)
May 9, 2022
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2022 With Webcast and Conference Call Today at 4:30 p.m. ET

Upcoming Events

May 09, 2022 at 4:30 PM EDT
Q2 2022 Enanta Pharmaceuticals Inc Earnings Conference Call